Poging GOUD - Vrij

Two to six, where is the fix?

Chronicle Pharmabiz

|

July 24, 2025

THERE is a debate going on in the circle of highly qualified pharmacists, especially among the pharmacy teachers, that, what should be the minimum duration of pharmacist course. This is intensified after the Pharmacy Council of India announced its decision of splitting B. Pharm course into B. Pharm Industrial and B. Pharm Clinical courses. But there are lot of voices for and few against the proposal. Some even suggesting entirely a new course. Let us discuss the pros and cons of all those views in brief.

- Prof. S. Balasubramanian

Two years pharmacist course

The people for it are conservatives or self-centered who do not want to disturb existing [for more than half a Century!] 2 years D. Pharm course. They are obviously not for the upgradation of the profession, as it may affect their business and profit! Resisting all move to upgrade the course with all their might and influence for decades, these people want to maintain status co. Now knowingly or unknowingly National Education Policy [NEP] also promotes their interest and PCI has announced it is for continuation of D. Pharm course and those who leave the B. Pharm course abruptly in the middle [after 2 years of course!] will be given Diploma in Pharmacy as per NEP. Is it not a super idea? Will they give similar diploma for the students who leave after second year MBBS? When there can be semi-baked pharmacists, why not half cooked doctors? They will make an excellent pair married to serve and save humanity! PCI which has announced earlier, its intension to abolish D. Pharm is now back tracking, simply to please their masters in the government by showing they have faithfully implemented NEP. It is more important than upgrading the profession, you know! It may be apt to quote here a para from my earlier article “Boot is on the other leg, come forward PCI” published in Pharmabiz dated 9.12.2020. “If a country is progressing means, it should upgrade its professional services by a diploma to degree to post graduate to doctoral to post-doctoral professional. Instead, we will retain all these level professional means where is the logic? Look at the developed countries, in pharmacy profession, they have moved from one year diploma to 6 years Pharm. D or M. Pharm [and stopping all short-term courses]. That is progress! Just to justify its action of prolonging D. Pharm, PCI is hiding behind NEP, we believe.” Remember it was written almost 5 years back!

Three years course

Chronicle Pharmabiz

Dit verhaal komt uit de July 24, 2025-editie van Chronicle Pharmabiz.

Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.

Bent u al abonnee?

MEER VERHALEN VAN Chronicle Pharmabiz

Chronicle Pharmabiz

Miltenyi Biotec, THSTI to set up cell mfg programme

IN a milestone step toward strengthening India's cell and gene therapy (CGT) ecosystem, Miltenyi Biotec, a global leader in CGT technologies, has signed a Letter of Intent (LOI) with the Translational Health Science and Technology Institute (THSTI) to establish India's first hands-on training programmes in clinical cell manufacturing.

time to read

1 min

August 21, 2025

Chronicle Pharmabiz

MDC asks Abbott Healthcare to avoid negligence while filing price details

THE Multi Disciplinary Committee (MDC) of Experts, which advises the National Pharmaceutical Pricing Authority (NPPA) on pricing matters, has directed Abbott Healthcare to avoid negligence in filing proper details while submitting the price related details in the Integrated Pharmaceutical Database Management System (IPDMS).

time to read

1 mins

August 21, 2025

Chronicle Pharmabiz

Greenspace Herbs unveils 'Quantum Ayurveda'

GREENSPACE Herbs, a leading botanical ingredients company, announced the commercial launch of Quantum Ayurveda, an advanced technology platform that enhances traditional herbal ingredients using quantum resonance principles.

time to read

1 min

August 21, 2025

Chronicle Pharmabiz

Chronicle Pharmabiz

Gandhi Automations ensuring clean room integrity with high-speed doors

GANDHI Automations Pvt Ltd offers prime clean reset high-speed doors to ensure clean room integrity, minimize air permeability and leakages.

time to read

3 mins

August 21, 2025

Chronicle Pharmabiz

Haryana DC officials raid unregistered clinic in Karnal

In a swift response to a complaint regarding illegal medical practice, a team of health and drug control officials raided an unregistered clinic in Karnal in Haryana, leading to the arrest of an individual found to be practicing medicine without proper medical qualification.

time to read

1 min

August 21, 2025

Chronicle Pharmabiz

Guj attracts investments from 100 cr to 5,000 cr

GUJARAT has attracted big ticket investments from MNCs and Indian companies as part of 376 Memorandum of Understandings (MoUs) ranging from Rs. 100 crore to Rs. 5,000 crore, informed Dr H G Koshia, Commissioner of the Gujarat Food & Drug Control Administration (FDCA).

time to read

1 min

August 21, 2025

Chronicle Pharmabiz

'Industry's diversification to EU markets is acting as a buffer against US trade shocks'

INDIAN Pharma industry's diversification into European markets is acting as a buffer against US trade shocks, says Parag Bhatia, director, Laborate Pharmaceuticals.

time to read

2 mins

August 21, 2025

Chronicle Pharmabiz

Pharma, CROs turn to hybrid cloud infra to safeguard patient information

PHARMA companies and clinical research organizations (CROs) are increasingly adopting hybrid cloud infrastructure to safeguard sensitive patient information.

time to read

2 mins

August 21, 2025

Chronicle Pharmabiz

'India's PLI scheme transforms pharma industry from policy to practice'

INDIA'S production linked incentive (PLI) scheme has emerged as a transformative policy aimed at revitalizing the pharmaceutical sector and its global competitiveness.

time to read

2 mins

August 21, 2025

Chronicle Pharmabiz

CDSCO cancels Proteos' Indian agent's import regn

THE Cosmetics Division of the Central Drugs Standard Control Organisation (CDSCO) has cancelled the registration certificate of NKG Advisory Business and Consulting Services to sell the cosmetic products of Spanish cosmetics maker Proteos Biotech, based on the former's request.

time to read

1 min

August 21, 2025

Listen

Translate

Share

-
+

Change font size